Cargando…

Pre-COVID-19 Immunity to Common Cold Human Coronaviruses Induces a Recall-Type IgG Response to SARS-CoV-2 Antigens Without Cross-Neutralisation

The capacity of pre-existing immunity to human common coronaviruses (HCoV) to cross-protect against de novo COVID-19is yet unknown. In this work, we studied the sera of 175 COVID-19 patients, 76 healthy donors and 3 intravenous immunoglobulins (IVIG) batches. We found that most COVID-19 patients dev...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyara, Makoto, Saichi, Melissa, Sterlin, Delphine, Anna, François, Marot, Stéphane, Mathian, Alexis, Atif, Mo, Quentric, Paul, Mohr, Audrey, Claër, Laetitia, Parizot, Christophe, Dorgham, Karim, Yssel, Hans, Fadlallah, Jehane, Chazal, Thibaut, Haroche, Julien, Luyt, Charles-Edouard, Mayaux, Julien, Beurton, Alexandra, Benameur, Neila, Boutolleau, David, Burrel, Sonia, de Alba, Sophia, Mudumba, Sasi, Hockett, Rick, Gunn, Cary, Charneau, Pierre, Calvez, Vincent, Marcelin, Anne-Geneviève, Combes, Alain, Demoule, Alexandre, Amoura, Zahir, Gorochov, Guy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8873934/
https://www.ncbi.nlm.nih.gov/pubmed/35222375
http://dx.doi.org/10.3389/fimmu.2022.790334
Descripción
Sumario:The capacity of pre-existing immunity to human common coronaviruses (HCoV) to cross-protect against de novo COVID-19is yet unknown. In this work, we studied the sera of 175 COVID-19 patients, 76 healthy donors and 3 intravenous immunoglobulins (IVIG) batches. We found that most COVID-19 patients developed anti-SARS-CoV-2 IgG antibodies before IgM. Moreover, the capacity of their IgGs to react to beta-HCoV, was present in the early sera of most patients before the appearance of anti-SARS-CoV-2 IgG. This implied that a recall-type antibody response was generated. In comparison, the patients that mounted an anti-SARS-COV2 IgM response, prior to IgG responses had lower titres of anti-beta-HCoV IgG antibodies. This indicated that pre-existing immunity to beta-HCoV was conducive to the generation of memory type responses to SARS-COV-2. Finally, we also found that pre-COVID-19-era sera and IVIG cross-reacted with SARS-CoV-2 antigens without neutralising SARS-CoV-2 infectivity in vitro. Put together, these results indicate that whilst pre-existing immunity to HCoV is responsible for recall-type IgG responses to SARS-CoV-2, it does not lead to cross-protection against COVID-19.